Study #2024-0091
A phase 1 study of SRG-514 administered Intraoperatively to the site of tumor resection of Patients undergoing Breast-Conserving Cancer Surgery
MD Anderson Study Status
Enrolling
Treatment Agent
SRG-514
Description
This is a multicenter, first-in-human (FIH), open label, Phase 1 dose escalation and recommended Phase 2 dose (RP2D) extension trial with a primary objective to define the RP2D of SRG-514 when administered intraoperatively to patients undergoing breast-conserving cancer surgery. SRG-514 will be investigated utilizing a 3+3 convention dose escalation cohorts.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Breast Cancer
Study phase:
Phase I
Physician name:
Isabelle Bedrosian
Department:
Breast Surgical Oncology
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.